Diseases / Autoimmune Diseases
Autoimmune Diseases
DiseaseAutoimmune diseases are conditions in which the immune system mistakenly attacks the body's own tissues and organs. They comprise many disorders affecting multiple organ systems.
- Trials
- 776
- Recruiting
- 173
- Completed
- 340
- With results
- 108
Last revised
Pipeline
Phase by status
| Phase | Recruiting | Not yet | By invitation | Active | Completed | Terminated | Withdrawn | Suspended | Unknown | Approved for marketing | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Early Phase 1 | 20 | 11 | — | — | 5 | 1 | 1 | 2 | 6 | — | 46 |
| Phase 1 | 23 | 6 | 1 | 3 | 64 | 9 | 5 | 1 | 7 | — | 119 |
| Phase 1/2 | 12 | 8 | 2 | 3 | 13 | 8 | 4 | — | 3 | — | 53 |
| Phase 2 | 17 | 4 | — | 11 | 57 | 17 | 2 | — | 9 | — | 117 |
| Phase 2/3 | 4 | — | — | — | 3 | — | — | — | — | — | 7 |
| Phase 3 | 9 | 1 | 1 | 6 | 33 | 6 | 2 | — | — | — | 58 |
| Phase 4 | 4 | 1 | 1 | 1 | 13 | 1 | — | — | 5 | — | 26 |
| Not applicable | 36 | 9 | — | 3 | 54 | 3 | 1 | 1 | 15 | — | 122 |
| Unknown | 48 | 12 | 6 | 6 | 98 | 10 | 6 | — | 41 | 1 | 228 |
Trials started per year
Conditions studied, by phase
| Condition | Early Phase 1 | Phase 1 | Phase 1/2 | Phase 2 | Phase 2/3 | Phase 3 | Phase 4 | Not applicable | Unknown | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Autoimmune Diseases | 46 | 119 | 53 | 117 | 7 | 58 | 26 | 122 | 228 | 776 |
| Lupus Erythematosus, Systemic | 13 | 28 | 12 | 15 | — | 19 | 5 | 15 | 19 | 126 |
| Immune System Diseases | 1 | 15 | 8 | 26 | — | 19 | 2 | 11 | 25 | 107 |
| Arthritis, Rheumatoid | 2 | 12 | 6 | 12 | 1 | 6 | 2 | 12 | 27 | 80 |
| Multiple Sclerosis | 1 | 12 | 9 | 8 | — | 2 | — | 16 | 15 | 63 |
| Diabetes Mellitus, Type 1 | — | 7 | 6 | 14 | — | 2 | 2 | 15 | 15 | 61 |
| Scleroderma, Systemic | 8 | 15 | 5 | 4 | 4 | 2 | 1 | 6 | 8 | 53 |
| Diabetes Mellitus | — | 6 | 5 | 6 | — | 2 | 4 | 12 | 3 | 38 |
| Connective Tissue Diseases | 1 | 7 | — | 7 | — | 10 | 2 | 3 | 6 | 36 |
| Sjogren's Syndrome | 5 | 4 | 2 | 9 | — | 3 | — | 1 | 11 | 35 |
Most active sponsors
| # | Sponsor | Trials | Phase 3 |
|---|---|---|---|
| 1 | National Institute of Allergy and Infectious Diseases (NIAID) | 22 | 1 |
| 2 | GlaxoSmithKline | 18 | 1 |
| 3 | Assistance Publique - Hôpitaux de Paris | 17 | 0 |
| 4 | National Heart, Lung, and Blood Institute (NHLBI) | 13 | 0 |
| 5 | Novartis Pharmaceuticals | 11 | 4 |
| 6 | Peking Union Medical College Hospital | 11 | 0 |
| 7 | National Cancer Institute (NCI) | 10 | 0 |
| 8 | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | 8 | 0 |
| 9 | Cabaletta Bio | 7 | 2 |
| 10 | Human Genome Sciences Inc., a GSK Company | 7 | 5 |
Most studied interventions
| # | Intervention | Trials |
|---|---|---|
| 1 | Cyclophosphamide | 26 |
| 2 | Blood Specimen Collection | 21 |
| 3 | fludarabine | 21 |
| 4 | belimumab | 16 |
| 5 | Rituximab | 14 |
| 6 | Prednisone | 12 |
| 7 | Mycophenolic Acid | 11 |
| 8 | Methotrexate | 9 |
| 9 | Standard of Care | 9 |
| 10 | Cyclosporine | 8 |
Evidence
- Results reported
- 31.8%108 of 340 completed
- Published
- 17.6%60 of 340 completed
- Primary endpoint met
- 31.8%21 of 66 analyses
- Median months to report
- 12
Documents disclosed
Trial profile
- Median enrollment
- 60
- Median duration
- 35.8months
- Countries
- 83
- Study sites
- 6788
Who is enrolled
Median enrollment by phase
- Early Phase 1
- 20
- Phase 1
- 24
- Phase 1/2
- 24
- Phase 2
- 54
- Phase 2/3
- 66
- Phase 3
- 231
- Phase 4
- 104
- Not applicable
- 48
- Unknown
- 275
Where trials run
Busiest cities
| # | City | Country | Trials |
|---|---|---|---|
| 1 | Houston | United States | 67 |
| 2 | Bethesda | United States | 66 |
| 3 | New York | United States | 65 |
| 4 | Boston | United States | 56 |
| 5 | Los Angeles | United States | 52 |
| 6 | London | United Kingdom | 46 |
| 7 | Beijing | China | 45 |
| 8 | Chicago | United States | 44 |
| 9 | Philadelphia | United States | 40 |
| 10 | Barcelona | Spain | 39 |
Terminations
- Terminated
- 55
- Withdrawn
- 21
- Suspended
- 4
- Stopped for recruitment
- 1.5%12 of 776 trials
Stated reasons
Reasons are grouped from the sponsor's own wording with a rule-based classifier; the original text is shown below.
Recently stopped
| Trial | Status | Stated reason | Stopped |
|---|---|---|---|
| NCT07604792 Suspended | Suspended | Enrollment is suspended to address regulatory requirements. Follow-up of currently enrolled participants continues as planned. | 2041-11-30 |
| NCT05627089 Withdrawn | Withdrawn | Decided not to move forward | 2035-01-01 |
| NCT07006805 Withdrawn | Withdrawn | The study was withdrawn prior to site activation and before enrollment of any participants due to sponsor decision to reprioritize the development portfolio. | 2029-10-31 |
| NCT06752876 Withdrawn | Withdrawn | Sponsor Strategic Pipeline Prioritization with Focus on CB-010 and CB-011 Oncology Programs | 2029-04-30 |
| NCT06677710 Suspended | Suspended | Business Reasons | 2028-12-31 |
| NCT03461419 Suspended | Suspended | Withdrawn \[COVID restrictions prevent patient enrollment or treatment. Clinical Trial facility is being closed due to viral limitations and loss of staff to perform\] | 2028-12-15 |
| NCT05480657 Withdrawn | Withdrawn | Study withdrawn | 2028-08-31 |
| NCT06549296 Suspended | Suspended | R\&D strategy adjustment | 2027-08-01 |
| NCT06291415 Withdrawn | Withdrawn | Sponsor decision | 2026-11-30 |
| NCT05678374 Terminated | Terminated | We had initially planned to include 60 participants per group. However, due to substantial difficulties with participant recruitment, we decided to close the study after enrolling 39, 15, and 40 participants in the respective groups. | 2026-08-18 |
Trial records
Individual study records live on ClinicalTrials.gov. A sample of the trials counted above:
Search all Autoimmune Diseases trials on ClinicalTrials.gov →